Maternal Third-Trimester TRAb Is Associated with Neonatal Thyroid Dysfunction and 24-Month Offspring Neurodevelopment: A Bidirectional Cohort Study
Authors' conclusion
Higher maternal third-trimester TRAb levels were associated with both neonatal thyroid dysfunction and abnormal neurodevelopmental screening results at 24 months in offspring of mothers with GD. This association with neurodevelopmental screening results may not be explained primarily by neonatal thyroid function alone.
Study context
- Population
- Pregnant women with Graves' disease (GD) and their offspring delivered between January 1, 2019, and December 31, 2023
- Participants
- 159 neonates
- Exposure
- Maternal GD-related thyroid factors (TSH, FT4, TRAb, antithyroid drug exposure) and neonatal thyroid function/neurodevelopment
- Outcome
- Associations of maternal third-trimester TRAb with neonatal thyroid dysfunction and abnormal neurodevelopmental screening at 24 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Higher maternal third-trimester TRAbOdds ratio (CI)P value
Neonatal thyroid dysfunction; independently associated
1.59(1.29–1.97)
P < 0.001Abnormal neurodevelopmental screening at 24 months; independently associated
1.15(1.04–1.27)
P = 0.005- Neonatal thyroid dysfunction
- 60 (37.7%)
- Abnormal neurodevelopmental screening at 24 months
- 23 (16.1%)
Observational data: associations, not effects.
Further findings
- Exploratory mediation analysis did not support a significant mediating role of neonatal TSH
Original publication
Maternal Third-Trimester TRAb Is Associated with Neonatal Thyroid Dysfunction and 24-Month Offspring Neurodevelopment: A Bidirectional Cohort Study. Thyroid. Published 3 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →